Insurance Technology Industry News

TMCNet:  Electromed, Inc. Reports FY2013 First Quarter Results

[November 13, 2012]

Electromed, Inc. Reports FY2013 First Quarter Results

NEW PRAGUE, Minn. --(Business Wire)--

Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three-month period ended September 30, 2012. Net revenues for the three months ended September 30, 2012 were approximately $4,031,000, a 25.1% decrease compared to net revenues of approximately $5,379,000 for the same period last year. The Company also announced a net loss of approximately $71,000, or $0.01 per basic and diluted share, for the three months ended September 30, 2012, compared to net income of approximately $246,000, or $0.03 per basic and diluted share, for the same period last year. Net revenues decreased in correlation with turnover in the sales force and a decrease in the number of Clinical Area Managers (CAMs) with over one year of experience, as well as lower referral counts. Net loss results were attributable to lower net revenues, offset by decreased expenses related to decreases in sales force and operating efficiencies designed to better align expenses with demand.

Gross profit decreased to approximately $2,821,000, or 70.0% of net revenues, for the three months ended September 30, 2012, compared to $4,069,000, or 75.6% of net revenues, for the same period in Fiscal 2012. The decrease in gross profit dollars resulted primarily from the decrease in sales volume. The change in gross profit percentage for the three-month period ended September 30, 2012 was primarily the result of lower than average reimbursement from the Company's mix of referrals compared to the three-month period ended September 30, 2011. Factors such as diagnoses that are not assured of reimbursement and insurance programs with lower allowable reimbursement amounts (for example, state Medicaid programs) affect average reimbursement received on a short-term basis. These factors tend to cause margins to fluctuate on a quarterly basis. However, management does not believe the results of the quarter ended September 30, 2012 are indicative of a long-term decrease in margins.

Operating expenses, which consist of selling, general, and administrative expenses and research and development expenses, were approximately $2,917,000 for the three months ended September 30, 2012, a decrease of approximately 17.2% over total operating expenses for the same period last year. The decrease primarily resulted from lower sales volume and lower associated selling and patient training costs; decreased payroll as a result of lower commissions and lower overall management compensation; and a reduction in marketing fees. Lower research and development expenses were due primarily to discontinuing the use of a certain outside vendor.

Total cash and cash equivalents were approximately $1,483,000 as of September 30, 2012. For the three months ended September 30, 2012, cash used in financing activities was approximately $110,000, consisting of payments on long-term debt and capital lease obligations. An aggregate of $224,000 was used for investing activities during the three months ended September 30, 2012, including $27,000 in payments for patent-related costs and $197,000 in expenditures for property and equipment. Net cash provided by operating activities was approximately $114,000, composed primarily of a decrease in the Company's receivable position of approximately $435,000, or 4.0%, to approximately $10,400,000 during the three months ended September 30, 2012. The change in total cash position was a decrease of approximately $220,000, as compared to a decrease of $1,146,000 during the same period in calendar year 2011.

Jim Cassidy, Ph.D., Electromed's Interim CEO, said "We continued to experience turnover in our sales force during the first quarter. Midway through the quarter we added to the strength of our management team by hiring a new Director of Sales. Subsequent to the end of the quarter, we realigned sales territories and instituted a new compensation plan designed to drive future sales growth. We saw significant improvement in sales performance in October that we attribute to those changes. We also brought marketing functions in-house at considerable savings and sought operating efficiencies throughout our organization to bring expenses in line with demand. These efforts are ongoing and are expected to contribute to improvements in profitability in the future."

About Electromed, Inc.
Electromed, Inc., founded in 1992 and headquartered in New Prague, Minnesota, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System and related products to patients with compromised pulmonary function. Further information about the Company can be found at

Cautionary Statements
Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words. Forward-looking statements made in this release include the Company's plans and expectations regarding long-term margins, future sales growth and profitability. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the impact of emerging and existing competitors, the effectiveness of our sales and marketing initiatives, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking statements," as such statements speak only as of the date of this release.

Electromed, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
September 30, June 30,
2012 2012
Assets (Unaudited)
Current Assets
Cash and cash equivalents $


$ 1,702,435
Accounts receivable (net of allowances for doubtful accounts of $45,000) 10,415,488 10,850,859
Inventories 2,305,276 2,392,416
Prepaid expenses and other current assets 463,426 359,583
Income tax receivable 405,494 340,744
Deferred income taxes   656,000     656,000  
Total current assets 15,728,239 16,302,037
Property and equipment, net 3,254,872 3,170,014
Finite-life intangible assets, net assets, net 1,167,136 1,174,033

Other assets

  290,689     274,940  
Total assets $


  $ 20,921,024  
Liabilities and Equity
Current Liabilities
Revolving line of credit $


$ 1,768,128
Current maturities of long-term debt 159,869 254,020
Accounts payable 554,086 749,985
Accrued compensation 484,812 636,995
Warranty reserve 604,000 610,000

Other accrued liabilities

  165,144     151,558  
Total current liabilities 3,736,039 4,170,686
Long-term debt, less current maturities 1,374,353 1,390,003
Deferred income taxes   280,000     280,000  
Total liabilities   5,390,392     5,840,689  
Commitments and Contingencies
Shareholders' Equity

Common stock, $0.01 par value; authorized: 13,000,000; shares; issued and outstanding: 8,114,252

81,143 81,143
Additional paid-in capital 13,000,453 12,959,136
Retained earnings   1,968,948     2,040,056  
Total equity  


Total liabilities and equity $


  $ 20,921,024  
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Income
(Unaudited) For the Three Months Ended
September 30,
2012   2011
Net revenues $ 4,031,286 $ 5,378,918
Cost of revenues   1,210,452     1,309,565  
Gross profit   2,820,834     4,069,353  
Operating expenses
Selling, general and administrative 2,816,015 3,399,806
Research and development   101,189     217,085  
Total operating expenses   2,917,204     3,616, 891  
Operating income (loss) (96,370) 452,462
Interest expense, net of interest income of $4,348 and $2,027 respectively   36,738     43,923  
Net income (loss) before income taxes (133,108) 408,539
Income tax benefit (expense)   62,000     (163,000 )
Net income (loss) $ (71,108)   $ 245,539  
Earnings (loss) per share:
Basic and diluted $ (0.01)   $ 0.03  
Weighted-average common shares outstanding:
Basic   8,114,252     8,100,915  
Diluted   8,114,252     8,119,190  
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(Unaudited) For the Three Months Ended
September 30,
2012   2011
Cash Flows From Operating Activities
Net income (loss) $ (71,108 ) $ 245,539

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Depreciation 114,979 90,552
Amortization of finite-life intangible assets 33,969 30,006
Amortization of debt issuance costs 3,363 3,297
Share-based compensation expense 41,317 31,053
Loss on disposal of property and equipment 3,915 9,864
Changes in operating assets and liabilities:
Accounts receivable 435,371 (807,361 )
Inventories 87,140 (307,845
Prepaid expenses and other assets (187,706 ) (77,186 )
Accounts payable and accrued liabilities   (347,226 )   (40,754  
Net cash provided by (used in) operating activities   114,014     (822,835 )
Cash Flows From Investing Activities
Expenditures for property and equipment (197,020 ) (215,311 )
Expenditures for finite-life intangible assets   (27,073 )   (21,750 )
Net cash used in investing activities   (224,093 )   (237,061 )
Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations (109,801 ) (109,970 )
Proceeds from options/warrants exercises - 1,800
Proceeds from subscription notes receivable   -     22,500  
Net cash used in financing activities   (109,801 )   (85,670 )
Net decrease in cash and cash equivalents (219,880 ) (1,145,566 )
Cash and cash equivalents
Beginning of period   1,702,435     4,091,739  
End of period $ 1,482,555   $ 2,946,173  

[ Back To Insurance Technology's Homepage ]